%0 Journal Article %A Yiqing Xia %A Huiting Ma %A David L Buckeridge %A Marc Brisson %A Beate Sander %A Adrienne Chan %A Aman Verma %A Iris Ganser %A Nadine Kronfli %A Sharmistha Mishra %A Mathieu Maheu-Giroux %T Mortality trends and lengths of stay among hospitalized COVID-19 patients in Ontario and Québec (Canada): a population-based cohort study of the first three epidemic waves %D 2021 %R 10.1101/2021.12.07.21267416 %J medRxiv %P 2021.12.07.21267416 %X Background Epidemic waves of COVID-19 strained hospital resources. We describe temporal trends in mortality risk and length of stay in intensive cares units (ICUs) among COVID-19 patients hospitalized through the first three epidemic waves in Canada.Methods We used population-based provincial hospitalization data from Ontario and Québec to examine mortality risk and lengths of ICU stay. For each province, adjusted estimates were obtained using marginal standardization of logistic regression models, adjusting for patient-level characteristics and hospital-level determinants.Results Using all hospitalizations from Ontario (N=26,541) and Québec (N=23,857), we found that unadjusted in-hospital mortality risks peaked at 31% in the first wave and was lowest at the end of the third wave at 6-7%. This general trend remained after controlling for confounders. The odds of in-hospital mortality in the highest hospital occupancy quintile was 1.2 (95%CI: 1.0-1.4; Ontario) and 1.6 (95%CI: 1.3-1.9; Québec) times that of the lowest quintile. Variants of concerns were associated with an increased in-hospital mortality. Length of ICU stay decreased over time from a mean of 16 days (SD=18) to 15 days (SD=15) in the third wave but were consistently higher in Ontario than Québec by 3-6 days.Conclusion In-hospital mortality risks and lengths of ICU stay declined over time in both provinces, despite changing patient demographics, suggesting that new therapeutics and treatment, as well as improved clinical protocols, could have contributed to this reduction. Continuous population-based monitoring of patient outcomes in an evolving epidemic is necessary for health system preparedness and response.Competing Interest StatementMM-G reports an investigator-sponsored research grant from Gilead Sciences Inc. MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., and contractual arrangements from the Institut national de santé publique du Québec (INSPQ), the Institut d'excellence en santé et services sociaux (INESSS), the World Health Organization, and the Joint United Nations Programme on HIV/AIDS (UNAIDS), all outside of the submitted work. NK reports research funding from Gilead Sciences, advisory fees from Gilead Sciences, ViiV Healthcare, Merck and Abbvie, and speaker fees from Gilead Sciences and Merck, all outside of the submitted work.Funding StatementThis work was supported by McGill's Interdisciplinary Initiative for Infection and Immunity (Mi4) (to MM–G) and a grant from the Canadian Institutes of Health Research (to SM). YX is supported by a doctoral award from the Fonds de recherche du Québec – Santé (FRQS). BS research program is funded by a Canada Research Chair (Tier 2) in Economics of Infectious Diseases; MM–G research program is funded by a Canada Research Chair (Tier 2) in Population Health Modeling; NK is supported by a career award from the Fonds de Recherche Québec – Santé (FRQS; Junior 1); and SM research program is funded by a Canada Research Chair (Tier 2) in Mathematical Modeling and Program Science.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approvals were obtained from the Health Sciences Research Ethics Board of University of Toronto (no. 39253) in Ontario, and the Institutional Review Board of Faculty of Medicine and Health Sciences of McGill University in Québec (A06-M52-20B).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are not available to the public. %U https://www.medrxiv.org/content/medrxiv/early/2021/12/08/2021.12.07.21267416.full.pdf